Ingevity reports Q2 adjusted EPS $1.39, consensus $1.16

Reports Q2 revenue $365.1M, consensus $378.7M. The company said, “Net sales of $365.1 million declined 7% primarily due to lower sales in the Performance Chemicals segment…Our strong profitability, robust free cash flow and improved leverage this quarter demonstrate our successful execution as well as the strength and resilience of our business model. We are also advancing our portfolio evaluation with a focus on retaining and investing in businesses that leverage our core competencies and also allow us to continue driving sustainable growth and delivering best-in-class EBITDA margins.”